HC Wainwright & Co. Reiterates Buy on Kymera Therapeutics, Maintains $46 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Kymera Therapeutics (NASDAQ:KYMR) and maintained a price target of $46.
May 24, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Kymera Therapeutics and maintained a price target of $46.
The reiteration of a Buy rating and the maintenance of a $46 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100